TABLE OF CONTENTS

Acknowledgment of Reviewers ................................................................. 467
In This Issue ............................................................................................ 469
From the IASLC Tobacco Control Committee ........................................ 474

EDITORIALS

Spotlight on Camrelizumab in Advanced Squamous Lung Cancer: Another
Feather in the Cap of Chinese Checkpoint Inhibitors ............................... 477
Noemi Reguart, MD, PhD, and Roxana Reyes, MD

The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in
the Therapy of Advanced NSCLC ............................................................. 481
Fen Wang, MD, and Qing Zhou, MD

Is Hypofractionation a Good Idea in Radiotherapy for Locally Advanced
NSCLC? .................................................................................................... 487
Paul Martin Putora, PhD, and Dirk K. De Ruyscher, MD, PhD

About the Cover: the cover image is from Figure 1 in
the article by Folch on page 519.
EDITORIAL: LUNG CANCER WORLDWIDE

Lung Cancer in Sudan
Moawia Mohammed Ali Elhassan, MMed Rad Onc, FC Rad Onc,
Ahmed Abdalla Mohamedani, DCP, FRCPath, Sahar Abdelrahman Hamid Mohamed, MD,
Anas Osman Ahmed Hamdoun, FRCR, FFR, RCSi, Dafalla Omer Abuidris, FC Rad Onc,
Alsideeg Mohammed Alamin Mohammed, MD, and Khalid Dafaallah Awadelkarim, PhD

CONTROVERSIES IN THORACIC ONCOLOGY

Chemotherapy
PD-1/PD-L1 Blockade Should Not Be the Preferred Option
in the Neoadjuvant Therapy of NSCLC
Lizza E. L. Hendriks, MD, PhD, Jordi Remon, MD, PhD, and Martin Reck, MD, PhD

Chemotherapy
PD-1/PD-L1 Blockade Should Be the Preferred Option in
the Neoadjuvant Therapy of NSCLC
Samuel Rosner, MD, and Patrick M. Forde, MB, BCh

REVIEW ARTICLE

The 2021 WHO Classification of Tumors of the Heart
Joseph J. Maleszewski, MD, Cristina Basso, MD, Melanie C. Bois, MD, Carolyn Glass, MD,
Kyle W. Klarich, MD, Charles Leduc, MD, Robert F. Padera, MD, PhD, and
Fabio Tavora, MD

ORIGINAL ARTICLES

Translational Oncology

NAVIGATE 24-Month Results: Electromagnetic Navigation Bronchoscopy for
Pulmonary Lesions at 37 Centers in Europe and the United States
Erik E. Folch, MD, MSc, Mark R. Bowling, MD, Michael A. Pritchett, DO, MPH,
Septimiu D. Murgu, MD, Michael A. Nead, MD, Javier Flandes, MD,
William S. Krimsky, MD, Amit K. Mahajan, MD, Gregory P. LeMense, MD,
Boris A. Murillo, MD, Sandeep Bansal, MD, Kelvin Lau, MD, Thomas R. Gildea, MD,
Merete Christensen, MD, Douglas A. Arenberg, MD, Jaspal Singh, MD, Krish Bhadra, MD,
D. Kyle Hogarth, MD, Christopher W. Towe, MD, Bernd Lamprecht, MD,
Michela Bezzi, MD, Jennifer S. Mattingley, MD, Kristin L. Hood, PhD, Haiying Lin, MS,
Jennifer J. Wolvers, BSc, and Sandeep J. Khandhar, MD, for the NAVIGATE Study
Investigators

Non-Small Cell Lung Cancer

Improving Outcomes in NSCLC: Optimum Dose Fractionation in
Radical Radiotherapy Matters
Michael Brada, BSc, MBChB, FRCR, FRCR, DSc, Helen Forbes, BSc, Susan Ashley, PhD,
and John Fenwick, PhD

(continued on next page)
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial ......................... 544
Shengxiang Ren, MD, Jianhua Chen, MD, Xingxiang Xu, MD, Tao Jiang, PhD, Ying Cheng, MD, Gongyan Chen, MD, Yueyin Pan, MD, Yong Fang, MD, Qiming Wang, MD, Yunchao Huang, MD, Wenxiu Yao, MD, Rui Wang, MD, Xingya Li, MD, Wei Zhang, MD, Yanjun Zhang, MD, Sheng Hu, MD, Renhua Guo, MD, Jianhua Shi, MD, Zhiwu Wang, MD, Peiguo Cao, MD, Donglin Wang, MD, Jian Fang, MD, Hui Luo, MD, Yi Geng, MD, Chunyan Xing, MD, Dongqing Lv, MD, Yiping Zhang, MD, Junyan Yu, MD, Shundong Cang, MD, Zeyu Yang, PhD, Wei Shi, MD, Jianjun Zou, MD, and Caicun Zhou, MD, on behalf of the CameL-sq Study Group

A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors................................................................................................ 558
Byoung Chul Cho, MD, PhD, Ji-Youn Han, MD, PhD, Sang-We Kim, MD, PhD, Ki Hyung Lee, MD, PhD, Eun Kyung Cho, MD, PhD, Yun-Gyoo Lee, MD, PhD, Dong-Wan Kim, MD, PhD, Joo-Hang Kim, MD, PhD, Gyeong-Won Lee, MD, PhD, Jong-Seok Lee, MD, PhD, Byoung Yong Shim, MD, PhD, Jin-Sooh Kim, MD, PhD, Sang Hoon Chun, MD, PhD, Sung Sook Lee, MD, PhD, Hye Ryun Kim, MD, PhD, Min Hee Hong, MD, Jin Seok Ahn, MD, PhD, Jong-Mo Sun, MD, PhD, Youngjo Lee, MD, PhD, Dae Ho Lee, MD, PhD, Ji Ah Kang, MS, NaMi Lee, MS, Mi-Jung Kwon, PhD, Carin Espenschied, MS, Arielle Yablonovitch, PhD, and Myung-Ju Ahn, MD, PhD

Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease ............................................................................................ 568
Sai-Hong I. Ou, MD, PhD, Benjamin J. Solomon, MD, PhD, Alice T. Shaw, MD, PhD, Shirish M. Gadgeel, MD, Benjamin Besse, MD, PhD, Ross A. Soo, MBBS, PhD, Antonello Abbattista, BSc, Francesca Toffalorio, MD, PhD, Robin Wiltshire, MBChB, and Alessandra Bearz, MD

LETTERS TO THE EDITOR

Some Thoughts Concerning the Patient Adherence to Lung Computed Tomography Screening Reporting and Data System—Recommended Screening Intervals ................................................................. e45
Wen Tang, MM, Liu Lu, MM, Jia-Wei Gu, MM, and Hong-Lin Chen, PhD

Response to Letter to the Editor .................................................................. e47
Yannan Lin, MD, MPH, Mingzhou Fu, MD, MPH, MHI, Kosuke Inoue, MD, PhD, Christie Y. Jeon, ScD, and Ashley Elizabeth Prosper, MD

Genomically Metastatic, but Surgically Curable? ........................................ e49
Taichiro Goto, MD, PhD
Molecular Testing Identifies Ultra-Late Recurrences in Lung Carcinomas: Implications for Clinical Management
Soo-Ryum Yang, MD, and Natasha Rekhtman, MD, PhD